Vaccinex, Inc. is a biotechnology company engaged in the discovery and development of human monoclonal antibodies to treat a variety of serious diseases. The company's patented ACTIVMAb® technology allows for the direct selection of high affinity, fully human monoclonal antibodies that would be difficult or impossible to identify using other systems. Unique to this technology is the capability to recover fully functional human antibodies from libraries expressed in mammalian cells.

Vaccinex is utilizing its ACTIVMAb® discovery technology to create a pipeline of promising therapeutic antibodies for in-house development and co-development with world-class partners, as well as for client companies needing fee-based antibody discovery and research services. This strategy allows Vaccinex to generate near-term collaboration and service revenues to offset operating costs while building long-term value through the development of a broad portfolio of therapeutic antibody products. The company’s current antibody drug development efforts are focused on cancer, autoimmune and inflammatory diseases.

Vaccinex was founded in 1997 based on technology invented at the University of Rochester. The company has filed over 70 patent applications in the U.S. and abroad, four of which have issued. Vaccinex has raised more than $40 million in funding from venture and strategic investors. In addition, Vaccinex has been awarded $10 million in research grants, including two separate Advanced Technology Program (“ATP”) awards from the National Institute of Standards and Technology. The company is headquartered in Rochester, NY and currently employs approximately 50 research and drug development scientists and staff.